Correlation Between Phathom Pharmaceuticals and Akero Therapeutics

Can any of the company-specific risk be diversified away by investing in both Phathom Pharmaceuticals and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Phathom Pharmaceuticals and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Phathom Pharmaceuticals and Akero Therapeutics, you can compare the effects of market volatilities on Phathom Pharmaceuticals and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Phathom Pharmaceuticals with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Phathom Pharmaceuticals and Akero Therapeutics.

Diversification Opportunities for Phathom Pharmaceuticals and Akero Therapeutics

-0.7

Correlation Coefficient

Phathom Pharmaceuticals  Akero Therapeutics

Excellent diversification

The 3 months correlation between Phathom and Akero is -0.7. Overlapping area represents the amount of risk that can be diversified away by holding Phathom Pharmaceuticals and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Phathom Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Phathom Pharmaceuticals are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Phathom Pharmaceuticals i.e., Phathom Pharmaceuticals and Akero Therapeutics go up and down completely randomly.

Pair Corralation between Phathom Pharmaceuticals and Akero Therapeutics

Given the investment horizon of 90 days Phathom Pharmaceuticals is expected to under-perform the Akero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Phathom Pharmaceuticals is 2.2 times less risky than Akero Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Akero Therapeutics is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  2,796  in Akero Therapeutics on December 29, 2024 and sell it today you would earn a total of  1,562  from holding Akero Therapeutics or generate 55.87% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Phathom Pharmaceuticals  vs.  Akero Therapeutics

Phathom Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Phathom Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Akero Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Phathom Pharmaceuticals and Akero Therapeutics

The main advantage of trading using opposite Phathom Pharmaceuticals and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Phathom Pharmaceuticals position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.

The idea behind Phathom Pharmaceuticals and Akero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.